Actimo Labs

ACTIMO LABS IS A NEXT GENERATION CONTRACT RESEARCH ORGANISATION REVOLUTIONISING ANTIBODY DRUG DEVELOPMENT THROUGH AI-DRIVEN TOXICOLOGY SOLUTIONS

What sets Actimo Labs apart is its AI-first approach, which facilitates rapid iteration, scalability, and automation; traditionally challenging tasks for contract research organisations. Actimo Labs focuses on developing  in-silico models for antibody validation that predict off-target interactions faster than traditional wet-lab experiments, thus reducing costs and accelerating decision-making for pharmaceutical and biotech companies.

Built on algorithms and curated datasets, Actimo Labs’ AI platform offers precise epitope mapping and toxicity predictions, which minimises the need for extensive lab work and lowers financial risks in drug development. The in-silico solutions streamline antibody screening, allowing researchers to test and refine therapies with speed and accuracy, improving the chances of clinical success.

By integrating deep learning and advanced data modeling, Actimo Labs offers insights into antibody interactions, enabling researchers to identify potential risks early on. The team is also developing a scalable infrastructure to support broader applications in biotherapeutics, including antibodyantigen docking simulations and post-translational modification predictions, designed for seamless integration into existing pharmaceutical pipelines. The entire team completed The Validator, Startup Sprint, and The Accelerator - the complete suite of entrepreneurial programs through The Generator.

“I have been able to learn from many other startup veterans in offering me advice into the many ways a startup can grow and how the experience may be different for different people, but ultimately, all startup founders share the common trait of grit. With grit, you can stand through the bad times and eventually see a way out.” — Kailash Kumar Vin

Website: www.actimolabs.com